Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm in La Jolla, California and formerly, the President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. Mr. Bradbury has nearly 30 years of pharmaceutical industry experience. During his 18-year tenure at Amylin, the company launched three first-in-class medicines: Symlin, Byetta and Bydureon. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb in August 2012. Before joining Amylin, Mr. Bradbury held marketing and sales positions for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury currently serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private), Microdermis, Inc. (Private) and Profil Institute for Clinical Research (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council and the University of Miami’s Innovation Corporate Advisory Council. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.


Mr. Carruthers has served as the Chief Financial Officer and Secretary Nivalis Therapeutics since early 2015. From Previously, he served as Chief Financial Officer for Array BioPharma. Prior to joining Array BioPharma, Mr. Carruthers served as Chief Financial Officer of Sievers Instrument, and before joining Sievers, was the treasurer and controller for the Waukesha division of Dover Corporation. Mr. Carruthers was previously employed as an accountant with Coopers & Lybrand. Mr. Carruthers current and previous employer are publicly traded companies. Both of which Mr. Carruthers helped take public. Over his career, Mr. Carruthers has lead financings totaling in excess of $750 million and contributed to more than a dozen significant technology out-licensing transactions and sales of divisions or entire companies.   Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago


Mr. Keuer brings over 30 years of technical expertise in the biotechnology and pharmaceutical industries, including leadership positions with ARCA biopharma, Insmed, Baxter International, Somatogen and Monsanto. In his current position with ARCA, Tom has overall responsibility for the company’s technical development programs in the chemistry, manufacturing and controls (CMC) area, and also serves as the head of project management. Prior to ARCA, he was Senior Vice President of Insmed Therapeutic Proteins, with responsibility for all process development and manufacturing programs at the company, including leadership of the GMP manufacturing site in Boulder, CO. Prior to Insmed, Tom was Vice President of Engineering for Baxter International’s Bioscience Division, a position that involved global responsibility for all capital projects related to manufacturing of biotechnology products. Tom also served as Vice President of Manufacturing for Somatogen, Inc, a Boulder-based biotechnology company. He received his Masters of Science in Biochemical Engineering from Rice University as a Monsanto–sponsored delegate.


Dr. Marshall is currently miRagen’s President & CEO, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of BiOptix, Inc.


Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. While at Array, he was responsible for negotiation numerous deals with major pharmaceutical companies including Eli Lilly, AstraZeneca, Celgene to name a few. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen’s Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.